# Attovia Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Attovia Therapeutics, Inc.). ## Overview Attovia Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing next-generation biologic therapies for immune-mediated diseases with high unmet need. Its pipeline includes ATTO-1310, ATTO-2306 and ATTO-1091, which are designed using the company’s ATTOBODY biologics platform, alongside platform licensing and research collaborations such as the EndPath radioligand agreement. ## Products & services • ATTO-1310 biologic product candidate • ATTO-2306 biologic product candidate • ATTO-1091 biologic product candidate • ATTOBODY biologics platform • Platform licensing and research services - **Clinical-stage product candidates** (0%) — ATTO-1310 is the lead candidate and is being evaluated in early clinical development. - **Preclinical product candidates** (0%) — ATTO-2306, ATTO-1091 and other programs are being advanced through preclinical development. - **ATTOBODY platform** (0%) — The proprietary biologics platform supports the design of differentiated therapies for immune-mediated diseases. - **Licensing and collaboration services** (100%) — Attovia licenses platform technology and performs research services, including work for EndPath radioligand products. - ATTO-1310 clinical-stage biologic candidate - ATTO-2306 preclinical biologic candidate - ATTO-1091 preclinical biologic candidate - ATTOBODY platform for next-generation biologics - Radioligand platform licensing through EndPath ## Customers Attovia’s current commercial counterparties are biotechnology companies and strategic partners seeking access to its ATTOBODY technology, exemplified by EndPath’s exclusive worldwide license for radioligand products and related research services. Potential future customers include patients, physicians, hospitals, specialty pharmacies and public or private payors if Attovia obtains approval for its product candidates. Product adoption would depend on clinical benefit, safety, physician acceptance and reimbursement coverage. - **Biotechnology and pharmaceutical partners** (primary) — License Attovia technology or collaborate on development of biologic and radioligand programs. - **Clinical research and development partners** (secondary) — Support preclinical studies, clinical trials, manufacturing and regulatory development activities. - **Physicians and healthcare providers** (emerging) — Could prescribe Attovia therapies if candidates demonstrate safety, efficacy and regulatory approval. - **Patients with immune-mediated diseases** (emerging) — Potential end users seeking improved treatment options for diseases with unmet medical need. - **Third-party payors** (emerging) — Public and private insurers may determine coverage and reimbursement for approved products. - Biotechnology partners license ATTOBODY technology for new therapies - EndPath receives radioligand rights and research support - Future physicians may prescribe approved immune therapies - Public and private payors may reimburse approved products - Patients use therapies addressing immune-mediated diseases ## Geography Attovia is headquartered and organized in the United States, where its corporate, research and regulatory activities are managed. The company’s platform license with EndPath is worldwide, creating potential international exposure through partner-led development and commercialization. No country-level revenue or authoritative geographic revenue breakdown is disclosed in the available report excerpts. - U.S.-based corporate and biopharmaceutical operations - Clinical and preclinical development supports global approvals - EndPath agreement grants worldwide radioligand rights - Future sales could depend on international market access - No country-level revenue breakdown was disclosed ## Strategy Attovia is prioritizing development of ATTO-1310, ATTO-2306 and ATTO-1091 while expanding the ATTOBODY platform. The company plans to use third-party manufacturers, research organizations and potential strategic collaborators to advance programs and support eventual commercialization. Over time, it expects to build sales, marketing, market access and distribution capabilities if candidates receive regulatory approval. - **Advance lead pipeline candidates** (short-term) — Clinical validation is required to establish efficacy, safety and future product value. - **Expand the ATTOBODY platform** (medium-term) — Additional platform applications could broaden the pipeline and create partnering opportunities. - **Build development and commercialization infrastructure** (medium-term) — Internal and external capabilities will be needed for trials, regulatory filings and potential launches. - Advance ATTO-1310 through early clinical development - Move ATTO-2306 and ATTO-1091 through preclinical studies - Expand the ATTOBODY biologics platform - Use partnerships to fund and extend development capabilities - Build commercialization infrastructure after potential approvals ## Risks Attovia has a limited operating history, no approved products and no product-sales revenue, making its business dependent on successful clinical development and regulatory approval. ATTO-1310 is in early clinical development while ATTO-2306 and ATTO-1091 remain preclinical, so failed trials, safety findings or delays could materially impair the pipeline. The company also relies on external manufacturers, CROs, financing sources and potential collaborators, creating execution, funding and intellectual-property risks. - **Clinical and regulatory failure** [critical] — Drug candidates must demonstrate safety, efficacy, purity and potency before approval. - **Limited operating history and product concentration** [critical] — The company has no approved products and depends heavily on three principal candidates. - **Capital raising and dilution** [high] — Clinical development requires substantial funding before product revenue is available. - **Manufacturing and supply execution** [high] — Clinical and commercial supplies depend on CMOs or future internal capabilities. - **Commercial adoption and reimbursement** [high] — Approved therapies still require physician adoption, payor coverage and patient demand. - **Partner and license dependency** [medium] — Collaborations may be needed to develop, fund or commercialize programs. - Clinical candidates may fail efficacy or safety testing - FDA or foreign regulatory approval may be delayed or denied - No approved products means no product-sales revenue - External CROs and CMOs create execution and supply risks - Additional financing may dilute shareholders or be unavailable - Partners may receive rights to technology or future revenues ## Accounting Attovia prepares its financial statements under U.S. GAAP and relies on estimates for accrued research and development costs, stock-based compensation and the historical fair value of common stock. Collaboration revenue from the EndPath Agreement is recognized under ASC 606 as research and development services are performed, while variable consideration and customer deposits can defer revenue recognition. Milestone payments are accrued when achievement becomes probable, and royalties are recognized as cost of sales when related products are sold. - **Collaboration revenue recognition** — Revenue timing depends on performance obligations and contract consideration. - **Variable consideration and customer deposits** — A customer deposit liability can defer revenue recognition into future periods. - **Milestone payments** — Changes in probability can shift research and development expense between periods. - **Accrued research and development costs** — Management estimates affect operating expenses and accrued liabilities. - **Stock-based compensation and common-stock valuation** — Changes in estimates can materially affect operating expenses and equity. - **Royalty accounting** — Future product commercialization would create cost-of-sales obligations. - ASC 606 governs EndPath collaboration revenue recognition - R&D service performance affects timing of collaboration revenue - Customer deposits defer recognition of variable consideration - Milestones accrue when achievement becomes probable - R&D accrual estimates affect reported operating expenses - Stock-based compensation depends on valuation assumptions --- *Last updated: 2026-09-24T11:44:56.199270+00:00*